• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Veradigm Launches New AI Application for Powerful Revenue Cycle Insights for Independent Practices

    1/28/26 4:01:00 PM ET
    $MDRX
    EDP Services
    Technology
    Get the next $MDRX alert in real time by email

    New AI-driven application helps Revenue Cycle Services clients gain faster, clearer visibility into financial performance

    Veradigm® (OTC:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, today announced the launch of a new AI-enabled application for Veradigm Revenue Cycle Services (RCS) clients, designed to deliver faster, deeper revenue cycle insights and strengthen the value of ongoing performance reviews for independent practices.

    Independent practices continue to face rising administrative complexity and financial pressure, driven by denials, payment variability, staffing constraints, and limited analytic visibility into what is driving revenue leakage. Veradigm RCS directly addresses these challenges by combining technology, expertise, and operational support to help practices improve cash flow and reduce revenue cycle burden.

    Accelerating RCS Value with New AI-Enabled Application

    The new AI-enabled application is a web‑based analytics workspace used by Veradigm's Revenue Cycle Services teams as part of their performance review process with clients. Instead of manually preparing and stitching together reports, analysts can now access an AI‑generated view of denial trends, payment patterns, and operational bottlenecks in a single interface.

    The system automatically highlights anomalies, expands audit coverage, and surfaces emerging issues, allowing practices to see what is driving revenue leakage and where intervention is needed.

    Veradigm's new AI-enabled application is expected to reduce manual performance review preparation time by up to 25%, surface denial and payment trends automatically, and apply machine intelligence to expand audit coverage and reduce avoidable rework.

    "This application helps practices respond sooner to shifts in payment trends, denials, and operational bottlenecks," said Tehsin Syed, Chief Product and Technology Officer at Veradigm. "By automating manual steps and strengthening trend identification, we're giving practices clearer visibility into their financial performance at a more frequent cadence, going from feedback to visualization in minutes."

    Improving Financial Performance with Veradigm Revenue Cycle Services

    Veradigm RCS is an end-to-end revenue cycle management solution designed to optimize financial performance for medical practices, with teams supporting everything from communicating with health plans to coding and claims, while integrating into existing electronic health record (EHR) and practice management workflows.

    Veradigm RCS consistently delivers top-tier financial outcomes for independent practices, achieving a 98% first-pass clean claims rate, 99% net collections, and 3–5% average revenue improvement in the first year.*

    "Over the past 100 days, we have strengthened our senior technology leadership and focused our expert AI team on high-impact client enhancements, starting with revenue cycle," said Donald Trigg, CEO of Veradigm. "This new application is a clear example of that strategy, applying AI innovation to an already high‑performing revenue cycle solution to help independent practices under increasing financial pressure."

    Veradigm's new AI-enabled revenue cycle application reflects the company's continued investment in AI-driven solutions that improve productivity, elevate financial outcomes, and enhance the support clients receive from their RCS teams.

    For more information on Veradigm Revenue Cycle Services, visit www.veradigm.com.

    *Average results after first 12 months. Veradigm data on file, 2025.

    About Veradigm®

    Veradigm has a proven history of delivering clinical and revenue cycle solutions that help independent practices improve outcomes and financial performance. Our AI-forward data and technology also help over 20,000 provider practices connect with health plans and biopharma to eliminate inefficiencies, close care gaps, and create a more affordable health system.

    © 2026 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260128064490/en/

    For more information contact:



    Investors:

    Jenny Gelinas

    312-506-1237

    [email protected]



    Media:

    Amanda Cohen

    732-567-7607

    [email protected]

    Get the next $MDRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDRX

    DatePrice TargetRatingAnalyst
    3/19/2024$15.00 → $10.00Buy → Hold
    Deutsche Bank
    1/3/2024$11.00Equal Weight
    Barclays
    7/6/2023Buy → Hold
    Argus
    4/12/2023$13.00Equal-Weight
    Stephens
    2/1/2023$17.00 → $18.50Overweight → Neutral
    Piper Sandler
    12/7/2022$26.00Hold → Buy
    Argus
    11/9/2022$22.00 → $23.00Neutral → Buy
    Goldman
    11/4/2022$17.00Overweight
    Piper Sandler
    More analyst ratings

    $MDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP & Chief HR Officer Hammond Lisa was granted 58,140 shares, increasing direct ownership by 50% to 174,175 units (SEC Form 4)

    4 - Veradigm Inc. (0001124804) (Issuer)

    6/5/25 5:28:24 PM ET
    $MDRX
    EDP Services
    Technology

    SVP General Counsel Vakharia Tejal was granted 69,768 shares, increasing direct ownership by 22% to 387,476 units (SEC Form 4)

    4 - Veradigm Inc. (0001124804) (Issuer)

    6/5/25 5:22:40 PM ET
    $MDRX
    EDP Services
    Technology

    Director Sacks Jonathan S was granted 46,512 shares and converted options into 8,696 shares (SEC Form 4)

    4 - Veradigm Inc. (0001124804) (Issuer)

    6/3/25 9:28:21 PM ET
    $MDRX
    EDP Services
    Technology

    $MDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Stonehill Capital Management Llc bought $66,001,500 worth of shares (10,222,875 units at $6.46) (SEC Form 4) (Amendment)

    4/A - Veradigm Inc. (0001124804) (Issuer)

    3/15/24 5:16:45 PM ET
    $MDRX
    EDP Services
    Technology

    Stonehill Capital Management Llc bought $66,001,500 worth of shares (10,222,875 units at $6.46) (SEC Form 4)

    4 - Veradigm Inc. (0001124804) (Issuer)

    3/4/24 9:50:46 PM ET
    $MDRX
    EDP Services
    Technology

    $MDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Veradigm downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded Veradigm from Buy to Hold and set a new price target of $10.00 from $15.00 previously

    3/19/24 7:50:39 AM ET
    $MDRX
    EDP Services
    Technology

    Barclays initiated coverage on Veradigm with a new price target

    Barclays initiated coverage of Veradigm with a rating of Equal Weight and set a new price target of $11.00

    1/3/24 8:00:02 AM ET
    $MDRX
    EDP Services
    Technology

    Veradigm downgraded by Argus

    Argus downgraded Veradigm from Buy to Hold

    7/6/23 9:00:49 AM ET
    $MDRX
    EDP Services
    Technology

    $MDRX
    SEC Filings

    View All

    Veradigm Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Veradigm Inc. (0001124804) (Filer)

    1/20/26 4:10:24 PM ET
    $MDRX
    EDP Services
    Technology

    Veradigm Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation

    8-K - Veradigm Inc. (0001124804) (Filer)

    7/2/25 9:29:03 AM ET
    $MDRX
    EDP Services
    Technology

    Veradigm Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Veradigm Inc. (0001124804) (Filer)

    6/23/25 4:10:28 PM ET
    $MDRX
    EDP Services
    Technology

    $MDRX
    Leadership Updates

    Live Leadership Updates

    View All

    Veradigm Appoints Tehsin Syed as Chief Product and Technology Officer

    Healthcare IT Veteran - former AWS and Cerner senior executive - to lead and accelerate innovation across Veradigm's unique footprint Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, today appoints Tehsin Syed, a healthcare technology leader with over two decades of experience, as Chief Product and Technology Officer. Syed most recently served as General Manager, AWS Health AI (Amazon Web Services). Under his leadership, the organization scaled as a growth engine, with net-new products for ambient clinical documentation, genomics, and medical imaging, and interoperability elevated to enterprise grade - capabilities trusted by providers, payers, bioph

    11/3/25 4:01:00 PM ET
    $MDRX
    EDP Services
    Technology

    Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors

    Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025. "John is a highly accomplished executive whose 40 years of healthcare leadership experience spans earl

    9/25/25 8:01:00 AM ET
    $LUCD
    $MDRX
    $PAVM
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology

    Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership

    Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go

    3/18/25 4:47:00 PM ET
    $CMBM
    $DOMO
    $EVH
    Radio And Television Broadcasting And Communications Equipment
    Technology
    Computer Software: Prepackaged Software
    Other Consumer Services

    $MDRX
    Financials

    Live finance-specific insights

    View All

    Veradigm Amends and Extends Stockholder Rights Plan

    Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, today announced that its Board of Directors (the "Board") has approved an amendment to extend the Company's existing Stockholder Rights Plan for an additional six months (the "Rights Plan"). The Rights Plan, adopted on February 26, 2024, was due to expire at 5:00PM New York City time on August 20, 2025. Under the terms of the amendment to the Rights Plan, the scheduled expiration date of the Rights Plan has been extended to February 20, 2026. In addition, the amendment to the Rights Plan changes the triggering threshold such that the rights would become exercisable only if a person or group acquires bene

    8/20/25 4:01:00 PM ET
    $MDRX
    EDP Services
    Technology

    Veradigm to Release Business Update June 23rd and Host Investor Call June 24th

    Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that management plans to provide a business update after the close of regular stock market hours on June 23, 2025. Veradigm management plans to host an investor conference call and webcast the Company's update at 8:00 a.m. Eastern Time on June 24, 2025. Update Call Details Veradigm plans to distribute an announcement promptly after the close of regular stock market hours on Monday, June 23, 2025. The announcement will also be available at Veradigm investor relations website. To listen to the conference call, participants may log onto the Veradigm investor relations website. Participan

    6/18/25 5:27:00 PM ET
    $MDRX
    EDP Services
    Technology

    STAAR Surgical Announces Changes to Board of Directors

    STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

    4/24/25 5:00:00 PM ET
    $AZN
    $CRVL
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Specialty Insurers
    Finance

    $MDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Veradigm Inc.

    SC 13G - Veradigm Inc. (0001124804) (Subject)

    11/14/24 4:05:58 PM ET
    $MDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Veradigm Inc.

    SC 13G/A - Veradigm Inc. (0001124804) (Subject)

    11/14/24 1:11:13 PM ET
    $MDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Veradigm Inc.

    SC 13G/A - Veradigm Inc. (0001124804) (Subject)

    11/8/24 10:29:29 AM ET
    $MDRX
    EDP Services
    Technology

    $MDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Veradigm Launches New AI Application for Powerful Revenue Cycle Insights for Independent Practices

    New AI-driven application helps Revenue Cycle Services clients gain faster, clearer visibility into financial performance Veradigm® (OTC:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, today announced the launch of a new AI-enabled application for Veradigm Revenue Cycle Services (RCS) clients, designed to deliver faster, deeper revenue cycle insights and strengthen the value of ongoing performance reviews for independent practices. Independent practices continue to face rising administrative complexity and financial pressure, driven by denials, payment variability, staffing constraints, and limited analytic visibility into what is driving rev

    1/28/26 4:01:00 PM ET
    $MDRX
    EDP Services
    Technology

    Veradigm and Meperia Launch Industry-First 8-Way Match EDI Platform to Strengthen Healthcare Supply Chain Integrity

    A next-generation, hospital-first EDI platform delivering transparency, accuracy, and data governance to healthcare supply chains Veradigm® (OTC:MDRX), a leading provider of healthcare data, technology, and enterprise resource planning (ERP) solutions, and Meperia (now part of Genesis Automation Healthcare), a healthcare supply chain technology company specializing in AI-powered content and spend management solutions, announced today a strategic collaboration to launch a next-generation Electronic Data Interchange (EDI) solution, purpose-built for healthcare. This new EDI platform is designed to eliminate the friction, cost, and complexity of traditional EDI platforms through an industr

    1/15/26 4:01:00 PM ET
    $MDRX
    EDP Services
    Technology

    Veradigm Launches Enhanced Ambient Scribe Capabilities

    AI-powered solution includes multilingual support, structured diagnosis code recommendations, and clinical decision insights support tools for Veradigm EHR customers Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, today announced enhancements to the artificial intelligence (AI) enhanced Ambient Scribe solution for Veradigm EHR customers. This milestone reflects Veradigm's commitment to delivering evolved AI solutions that improve clinical documentation, support clinical decision-making, and enhance patient care. Since its launch last year, Veradigm Ambient Scribe has developed into a robust AI-powered solution that passively captures patient-provide

    11/17/25 8:01:00 AM ET
    $MDRX
    EDP Services
    Technology